Exemestane


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Adjuvant therapy for postmenopausal women w/ hormone receptor positive early breast cancer 25 mg once daily for 5 yr of combined adjuvant hormonal therapy (following tamoxifen). Advanced breast cancer 25 mg once daily until evident tumour progression.
Administration
Should be taken with food.
Contraindications
Premenopausal women. Pregnancy and lactation.
Special Precautions
Patient w/ uncontrolled HTN, osteoporosis and its potential causes (e.g. vit D deficiency, hyperthyroidism, hyperparathyroidism). Hepatic and renal impairment. Patient Counselling This drug may cause drowsiness, asthenia, and dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor 25-hydroxy vit D level and BMD prior to therapy; and LFT. Assess for new or unusual bone pain or swelling of face, lips, or throat.
Adverse Reactions
Significant: Decrease in BMD. Nervous: Headache, dizziness, depression, insomnia, anxiety, neuropathy, paraesthesia. CV: HTN. GI: Diarrhoea, nausea, abdominal pain, anorexia, constipation, vomiting. Resp: Dyspnoea. Musculoskeletal: Arthralgia, myalgia, carpal tunnel syndrome, osteoarthritis, osteoporosis. Ophthalmologic: Visual disturbances. Dermatologic: Hot flushes, alopecia, increased sweating, dermatitis, peripheral eodema, rash. Others: Fatigue.
Drug Interactions
Decreased plasma levels of exemestane when used w/ strong CYP3A4 enzyme inducers (e.g. phenytoin, carbamazepine, rifampicin). Antagonised effect w/ oestrogens.
ATC Classification
L02BG06 - exemestane ; Belongs to the class of enzyme inhibitors. Used in endocrine therapy.
Disclaimer: This information is independently developed by CIMS based on exemestane from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in